Zoledronic acid

also known as Zometa · aclasta · ZOL · zoledronate · ZOL446 · CGP42446 · Zoledronic Acid Injection · acid zoledronique · +8 more

Other / unclassified

Developed for: osteoporosis · breast cancer · prostate cancer · plasma cell myeloma · metastatic malignant neoplasm · postmenopausal osteoporosis · metastatic carcinoma in the bone · non-small cell lung carcinoma
+101 more
· bone Paget disease · metastatic neoplasm · breast carcinoma · breast neoplasm · female breast carcinoma · lung cancer · neuroblastoma · osteogenesis imperfecta · bone giant cell tumor · bone neoplasm · bone resorption disease · cancer · humoral hypercalcemia of malignancy · Hutchinson-Gilford progeria syndrome · osteonecrosis · progesterone-receptor positive breast cancer · prostate adenocarcinoma · disease of bone structure · disease related to hematopoietic stem cell transplant · estrogen-receptor positive breast cancer · Ewing sarcoma · gastric adenocarcinoma · hepatocellular carcinoma · hormone-resistant prostate carcinoma · kidney cancer · osteoarthritis, knee · osteosarcoma · pleural neoplasm · renal cell carcinoma · sarcoma · spinal cord injury · acute lymphoblastic leukemia · adenocarcinoma · alveolar soft part sarcoma · avascular necrosis · beta-thalassemia major · bone marrow disorder · bone remodeling disease · breast adenocarcinoma · carcinoma · cervical cancer · chondrosarcoma · chordoma · chronic recurrent multifocal osteomyelitis 3 · clear cell sarcoma · congenital dyserythropoietic anemia · corticosteroid-induced osteoporosis · cystic fibrosis · desmoplastic small round cell tumor · disease related to solid organ transplantation · epithelioid sarcoma · fallopian tube neoplasm · Her2-receptor negative breast cancer · hypercalcemia disease · invasive ductal breast carcinoma · leiomyosarcoma · lung neoplasm · lytic metastatic bone lesion · malignant epithelial tumor of ovary · malignant mesothelioma · malposition of teeth with or without hypodontia/oligodontia · metastatic carcinoma · metastatic prostate carcinoma · multidrug-resistant tuberculosis · muscular atrophy · myelofibrosis · myelofibrosis with myeloid metaplasia · myoepithelial tumor · nasopharyngeal carcinoma · nerve sheath neoplasm · neurogenic arthropathy · non-Hodgkin lymphoma · osteoarthritis, hip · osteoid osteoma · pancreatic adenocarcinoma · primary peritoneal carcinoma · renal osteodystrophy · respiratory system cancer · rhabdoid tumor · rhabdomyosarcoma · rheumatic disorder · sickle cell disease · small cell lung carcinoma · solitary osseous plasmacytoma · stroke disorder · synovial sarcoma · thalassemia · triple-negative breast carcinoma · urinary system neoplasm · wet macular degeneration · Wilms tumor · abnormal mineralization disorder · bone disorder · complex regional pain syndrome · extrapyramidal and movement disease · idiopathic inflammatory myopathy · impaired renal function disease · Parkinson disease · pelvic muscle wasting · primary hyperparathyroidism · rheumatoid arthritis
Investigated by: Novartis Pharmaceuticals · Novartis · National Cancer Institute (NCI) · Alliance for Clinical Trials in Oncology · Amgen · Massachusetts General Hospital
+231 more
· Boston Children's Hospital · Brigham and Women's Hospital · Dana-Farber Cancer Institute · James Graham Brown Cancer Center · M.D. Anderson Cancer Center · Mayo Clinic · National Institutes of Health (NIH) · Sun Yat-sen University · The Cleveland Clinic · University of Louisville · University of Sheffield · Washington University School of Medicine · 251 Hellenic Air Force & VA General Hospital · 424 General Military Hospital · Abbott · Assistance Publique - Hôpitaux de Paris · AstraZeneca · Chugai Pharmaceutical · Eastern Cooperative Oncology Group · Fudan University · Institut Cancerologie de l'Ouest · Leiden University Medical Center · McGill University Health Centre/Research Institute of the McGill University Health Centre · NCIC Clinical Trials Group · Nantes University Hospital · National Institute on Aging (NIA) · National Taiwan University Hospital · New Approaches to Neuroblastoma Therapy Consortium · Northwestern University · Odense University Hospital · SWOG Cancer Research Network · Sanofi · Schering-Plough · Stanford University · Tata Memorial Hospital · University of Alabama at Birmingham · University of Athens · Academy of Finland · Alberta Health services · All India Institute of Medical Sciences · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · American Academy of Orthopaedic Surgeons · American Society of Clinical Oncology · Antonio Lazzari · Aristotle University Of Thessaloniki · Asahi Kasei Therapeutics Corporation · Asan Medical Center · Assistance Publique Hopitaux De Marseille · Assiut University · Astellas Pharma Global Development, Inc. · Austrian Breast & Colorectal Cancer Study Group · Aventis Pharmaceuticals · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Baxter Healthcare Corporation · Baylor College of Medicine · Bayside Health · Beijing Municipal Science & Technology Commission · Beth Israel Deaconess Medical Center · Biologics, Inc. · Bristol-Myers Squibb · Calvary Mater Newcastle, Australia · Canadian Breast Cancer Foundation · Cancer Society of New Zealand · Cancer and Leukemia Group B · Central European Cooperative Oncology Group · Centre Leon Berard · Children's Hospital of Eastern Ontario · Children's Oncology Group · Chinese Academy of Medical Sciences · Chinese PLA General Hospital · Chonnam National University Hospital · Christian Medical College, Vellore, India · Chugai Pharma USA · City of Hope Medical Center · all 237 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (4)	US (FDA)	RECLAST	—	2008-06-03 – 2009-05-29	fda.gov ↗
Label expansions (2)	US (FDA)	ZOMETA	—	2004-02-27 – 2008-03-20	fda.gov ↗
Approved	US (FDA)	ZOMETA	—	2001-08-20	fda.gov ↗
Approved	EU (EMA)	Zometa	—	2001-03-20	europa.eu ↗

Trials 240 · started per year

today

EU approved 2001

US approved 2001

1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT05053750	Dec 2021 → Feb 2027 expected	fallopian tube neoplasm, malignant epithelial tumor of ovary, primary peritoneal carcinoma	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 115 trials
Phase 1	NCT07741136	Aug 2026 → Aug 2027 expected	chronic kidney disease, osteoporosis	University of Campinas, Brazil	Not yet recruiting	No outcome recorded
Phase 1	NCT05204836	May 2023 → Jul 2025	osteoarthritis, knee	University of Calgary	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT03862833	May 2019 → Aug 2023	disease related to hematopoietic stem cell transplant	Nantes University Hospital	Completed	No outcome recorded
Phase 1	NCT03173976	Jul 2017 → Apr 2023 overdue	chondrosarcoma	Mohammed Milhem	Active not recruiting	No outcome recorded
Phase 1	NCT01671774	Oct 2012 → Oct 2014	esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma	Astellas Pharma Global Development, Inc.	Completed	No outcome recorded
Phase 1	NCT01404702	Aug 2011 → Aug 2014	neuroblastoma	University of Alabama at Birmingham	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT01219790	Oct 2010 → Nov 2014	prostate adenocarcinoma	Institut Cancerologie de l'Ouest	Completed	No outcome recorded
Phase 1	NCT00892242	Dec 2009 → Apr 2013	adenocarcinoma	Washington University School of Medicine	Terminated	No outcome recorded
Phase 1	NCT00885326	Dec 2009 → Apr 2014	neuroblastoma	New Approaches to Neuroblastoma Therapy Consortium	Completed	No outcome recorded
Phase 1	NCT00807963	Dec 2008 → Sep 2009	osteoporosis	Halozyme Therapeutics	Completed	No outcome recorded
Phase 1	NCT00742924	Aug 2008 → Apr 2012	sarcoma	Children's Oncology Group	Completed	No outcome recorded
Phase 1	NCT00424983	Nov 2006 → Nov 2009	breast cancer, plasma cell myeloma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00264420	Dec 2005 → Mar 2007	breast cancer, lung cancer, lytic metastatic bone lesion, prostate cancer	The Cleveland Clinic	Completed	No outcome recorded
Phase 1	NCT00206388	Apr 2005 → Apr 2008	neuroblastoma	Baylor College of Medicine	Completed	No outcome recorded
Phase 1	NCT00004928	Oct 1999 → Oct 2004	prostate cancer	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded

Phase 1/29 trials
Phase 1/2	NCT07471516	Feb 2026 → Feb 2027 expected	congenital dyserythropoietic anemia	Institute of Hematology & Blood Diseases Hospital, China	Recruiting	No outcome recorded
Phase 1/2	NCT06625190	Feb 2026 → Feb 2030 expected	Ewing sarcoma, Wilms tumor, alveolar soft part sarcoma, chordoma +10	University of Florida	Recruiting	No outcome recorded
Phase 1/2	NCT06759064	Sep 2024 → Sep 2026 overdue	gastric adenocarcinoma	Qilu Hospital of Shandong University	Recruiting	No outcome recorded
Phase 1/2	NCT00566618	Nov 2007 → Nov 2020	breast cancer, metastatic carcinoma in the bone	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00639392	Jun 2007 → May 2008	sickle cell disease	Virginia Commonwealth University	Withdrawn	No outcome recorded
Phase 1/2	NCT00588913	Jan 2006 → Mar 2009	kidney cancer, metastatic malignant neoplasm	Tokyo Women's Medical University	Completed	No outcome recorded
Phase 1/2	NCT01564121	Jan 2006 → Jan 2011	bone giant cell tumor	Nantes University Hospital	Terminated	No outcome recorded
Phase 1/2	NCT00482378	Mar 2005 → May 2007	plasma cell myeloma	Mayo Clinic	Completed	No outcome recorded
Phase 1/2	NCT00060138	Nov 2002 → Sep 2004	breast cancer, humoral hypercalcemia of malignancy, metastatic carcinoma in the bone	Chugai Pharmaceutical	Completed	No outcome recorded
Phase 254 trials · 7 met primary · 3 missed
Phase 2	NCT07668583	Sep 2026 → Mar 2029 expected	chronic recurrent multifocal osteomyelitis 3	Assistance Publique - Hôpitaux de Paris	Not yet recruiting	No outcome recorded
Phase 2	NCT05080790	Nov 2021 → Jan 2025	leiomyosarcoma	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Completed	No outcome recorded
Phase 2	NCT04304755	Oct 2021 → Jan 2024	wet macular degeneration	Oslo University Hospital	Completed	No outcome recorded
Phase 2	NCT04742010	Feb 2021 → Nov 2023	bone resorption disease, muscular atrophy	Stinus Gadegaard Hansen	Completed	No outcome recorded
Phase 2	NCT03336983	Dec 2017 → Jun 2022	metastatic carcinoma in the bone, prostate cancer	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Completed	No outcome recorded
Phase 2	NCT02632903	Oct 2016 → Mar 2018	acute lymphoblastic leukemia, osteonecrosis, osteoporosis	Children's Hospital of Eastern Ontario	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT03073785	Sep 2016 → Dec 2027 expected	pancreatic adenocarcinoma	University of Nebraska	Active not recruiting	No outcome recorded
Phase 2	NCT02325414	Feb 2015 → Aug 2020	osteoporosis, spinal cord injury	Northwestern University	Completed	No outcome recorded
Phase 2	NCT02784652	Jun 2014 → Feb 2017	digestive system cancer, metastatic carcinoma in the bone	Severance Hospital	Completed	No outcome recorded
Phase 2	NCT01737216	Nov 2012 → Jan 2016	lung cancer	Hebei Tumor Hospital	Unknown	No outcome recorded
Phase 2	NCT01679080	Nov 2012 → Jul 2020	osteogenesis imperfecta	University of Aarhus	Terminated	No outcome recorded
Phase 2	NCT01332617	Apr 2011 → Feb 2018	plasma cell myeloma	University of Louisville	Withdrawn	No outcome recorded
Phase 2	NCT01194440	Feb 2011 → Jan 2014	ductal breast carcinoma in situ, estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Completed	No outcome recorded
Phase 2	NCT01228318	Jan 2011 → Apr 2017	HIV infectious disease, osteoporosis	Emory University	Completed	Met primary
Phase 2	NCT01259193	Oct 2010 → Jul 2011	hepatocellular carcinoma	Fudan University	Unknown	No outcome recorded
Phase 2	NCT01367288	Apr 2010 → Apr 2014	female breast carcinoma	Hospices Civils de Lyon	Completed	Missed primary
Phase 2	NCT00844480	Mar 2010 → Dec 2015	bone resorption disease	Thomas J. Schnitzer	Terminated	Met primary Stop: Enrollment
Phase 2	NCT01004510	Nov 2009 → Sep 2010	non-small cell lung carcinoma, pleural neoplasm	Peter Bushunow MD	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00966992	Aug 2009 → Mar 2010	cervical cancer	Washington University School of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00916747	Aug 2009 → Feb 2022	Hutchinson-Gilford progeria syndrome	Boston Children's Hospital	Unknown	Met primary
Phase 2	NCT00972959	Jul 2009 → May 2013	plasma cell myeloma	University of Athens	Completed	No outcome recorded
Phase 2	NCT00896532	Jun 2009 → Feb 2011	postmenopausal osteoporosis	Amgen	Completed	Met primary
Phase 2	NCT01204203	Jun 2009 → Apr 2015	malignant mesothelioma	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 2	NCT00879034	Mar → Apr 2009	Hutchinson-Gilford progeria syndrome	Boston Children's Hospital	Completed	Met primary
Phase 2	NCT00760370	Dec 2008 → Dec 2011	breast cancer, plasma cell myeloma	Vejle Hospital	Completed	No outcome recorded
Phase 2	NCT00889590	Dec 2008 → May 2015	bone giant cell tumor	Leiden University Medical Center	Terminated	Missed primary Stop: Enrollment
Phase 2	NCT00731016	Oct 2008 → Apr 2013	Hutchinson-Gilford progeria syndrome	Assistance Publique Hopitaux De Marseille	Completed	No outcome recorded
Phase 2	NCT00558272	Feb 2008 → Jan 2010	bone neoplasm, breast cancer, prostate cancer	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00636740	Feb 2008 → Feb 2009	hormone-resistant prostate carcinoma	Merrion Pharmaceuticals, LLC	Completed	No outcome recorded
Phase 2	NCT00477217	Jan 2008 → May 2009	osteonecrosis	Novartis	Withdrawn	No outcome recorded
Phase 2	NCT00577642	Oct 2007 → Dec 2012	plasma cell myeloma	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00525759	Jul 2007 → Jan 2010	breast cancer	Sheffield Teaching Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 2	NCT00301873	May 2006 → Feb 2011	malignant glioma, osteoporosis	Duke University	Completed	No outcome recorded
Phase 2	NCT00258765	May → Nov 2006	prostate cancer	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00287261	Feb 2006 → Mar 2008	myelofibrosis, myelofibrosis with myeloid metaplasia	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 2	NCT00263484	Dec 2005 → Oct 2008	plasma cell myeloma	Gleneagles Hospital	Completed	No outcome recorded
Phase 2	NCT00305695	Nov 2005 → Dec 2011	hereditary breast ovarian cancer syndrome, osteoporosis, ovarian carcinoma	Gynecologic Oncology Group	Completed	No outcome recorded
Phase 2	NCT00697619	Sep 2005 → Jan 2009	nasopharyngeal carcinoma	Sun Yat-sen University	Completed	Met primary
Phase 2	NCT00247650	Sep 2005 → Mar 2007	breast cancer	Novartis	Completed	No outcome recorded
Phase 2	NCT00321932	Jul 2005 → Mar 2011	leukemia, lymphoma, myelodysplastic syndrome, osteoporosis +1	University of Minnesota	Completed	No outcome recorded
Phase 2	NCT00265200	Feb 2005 → Aug 2009	metastatic neoplasm, non-small cell lung carcinoma, small cell lung carcinoma	University of Louisville	Terminated	No outcome recorded Stop: Business
Phase 2	NCT00554918	Feb 2005 → Dec 2008	metastatic malignant neoplasm, prostate cancer	University Hospital Birmingham	Completed	No outcome recorded
Phase 2	NCT00104650	Jan 2005 → Jan 2008	bone neoplasm	Amgen	Completed	Met primary
Phase 2	NCT00295867	Nov 2004 → Jun 2011	breast cancer	University of California, San Francisco	Completed	No outcome recorded
Phase 2	NCT00131118	Jul 2004 → May 2007	osteogenesis imperfecta	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00582790	Aug 2003 → Aug 2008	kidney cancer	University of Wisconsin, Madison	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00063479	Jun 2003 → May 2007	osteogenesis imperfecta	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00226954	Mar 2003 → Nov 2007	urinary system neoplasm	Stanford University	Terminated	No outcome recorded
Phase 2	NCT00242203	Oct 2002 → Aug 2007	breast neoplasm	Washington University School of Medicine	Completed	Missed primary
Phase 2	NCT00039104	Apr 2002 → Jan 2005	prostate adenocarcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00151073	Apr 2002 → Sep 2005	hormone-resistant prostate carcinoma	University of Michigan Rogel Cancer Center	Completed	No outcome recorded
Phase 2	NCT00172068	Jan 2002 → Nov 2008	breast cancer	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT00181558	Dec 2001 → Dec 2006	prostate adenocarcinoma	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00083382	Dec 1998 → May 2014	plasma cell myeloma	University of Arkansas	Completed	No outcome recorded

Phase 2/39 trials
Phase 2/3	NCT05106517	Sep 2021 → Mar 2023	—	Shenzhen People's Hospital	Unknown	No outcome recorded
Phase 2/3	NCT03289338	Jun 2016 → Dec 2018	neurogenic arthropathy	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2/3	NCT01654367	Jan → Dec 2012	breast cancer	Tianjin Medical University	Unknown	No outcome recorded
Phase 2/3	NCT01426555	Feb 2011 → Feb 2015	osteoporosis	Antonio Lazzari	Terminated	No outcome recorded
Phase 2/3	NCT01016093	Nov 2009 → Nov 2011	beta-thalassemia major	Tehran University of Medical Sciences	Unknown	No outcome recorded
Phase 2/3	NCT01344967	Feb 2009 → Aug 2011	metastatic carcinoma in the bone	University Health Network, Toronto	Completed	No outcome recorded
Phase 2/3	NCT00691236	May 2008 → May 2013	osteosarcoma	Tata Memorial Hospital	Unknown	No outcome recorded
Phase 2/3	NCT00297830	Nov 2005 → Apr 2010	bone resorption disease	Columbia University	Completed	No outcome recorded
Phase 2/3	NCT00268476	Jul 2005 → Mar 2026 overdue	prostate cancer	Medical Research Council	Active not recruiting	Mixed
Phase 378 trials · 19 met primary · 10 missed
Phase 3	NCT06221072	Apr 2024 → May 2027 expected	metastatic carcinoma in the bone	Shanghai JMT-Bio Inc.	Not yet recruiting	No outcome recorded
Phase 3	NCT05866172	May 2023 → Dec 2024	hepatocellular carcinoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 3	NCT05164952	Sep 2021 → Aug 2023	progesterone-receptor positive breast cancer	Assiut University	Unknown	No outcome recorded
Phase 3	NCT03951493	Jun 2020 → Nov 2023	metastatic malignant neoplasm	Institut Cancerologie de l'Ouest	Unknown	No outcome recorded
Phase 3	NCT03408652	Mar 2019 → Jun 2020	renal cell carcinoma	Centre Leon Berard	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT03295981	May 2018 → Jan 2027 expected	bone giant cell tumor	St. Louis University	Recruiting	No outcome recorded
Phase 3	NCT02516423	Nov 2016 → Sep 2024	solitary osseous plasmacytoma	Alliance for Clinical Trials in Oncology	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02739555	Jun 2016 → Apr 2018	osteoid osteoma	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02595138	Oct 2015 → Oct 2018	triple-negative breast carcinoma	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT01920568	Aug 2013 → Feb 2015	disease of bone structure	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02622607	Jan 2013 → Mar 2018	lung cancer	Tang-Du Hospital	Unknown	No outcome recorded
Phase 3	NCT01642901	Sep 2012 → Mar 2018	spinal cord injury	Thomas Jefferson University	Completed	No outcome recorded
Phase 3	NCT01522521	Feb 2012 → Jan 2015	osteoporosis	Asahi Kasei Therapeutics Corporation	Completed	Met primary
Phase 3	NCT01197300	Oct 2010 → Feb 2019	osteoporosis	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01166178	Oct 2010 → Jun 2012	multiple sclerosis, osteoporosis	Novartis	Terminated	No outcome recorded
Phase 3	NCT01099436	Apr 2010 → Apr 2012	breast cancer	Dutch Breast Cancer Research Group	Completed	Missed primary
Phase 3	NCT02838121	Dec 2009 → Jan 2013	—	Mel Shiuann-Sheng Lee	Completed	No outcome recorded
Phase 3	NCT00909961	Nov 2009 → Dec 2011	postmenopausal osteoporosis	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00987636	Oct 2009 → Mar 2019	Ewing sarcoma	University Hospital Muenster	Completed	Missed primary
Phase 3	NCT00939900	Jul 2009 → Jun 2012	avascular necrosis	Seoul National University Bundang Hospital	Completed	No outcome recorded
Phase 3	NCT00869206	Mar 2009 → Jun 2014	breast adenocarcinoma, metastatic malignant neoplasm, musculoskeletal system disorder, plasma cell myeloma	Alliance for Clinical Trials in Oncology	Completed	Met primary
Phase 3	NCT00799266	Dec 2008 → Mar 2018	osteoporosis	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT00718861	May 2008 → Apr 2013	postmenopausal osteoporosis	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00685646	May 2008 → Jan 2014	metastatic malignant neoplasm, prostate cancer	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	Completed	No outcome recorded
Phase 3	NCT00982124	Oct 2007 → Sep 2015	osteogenesis imperfecta	Shriners Hospitals for Children	Completed	No outcome recorded
Phase 3	NCT00470223	Mar 2007 → Dec 2015 overdue	sarcoma	UNICANCER	Active not recruiting	Missed primary
Phase 3	NCT00556374	Dec 2006 → Oct 2014	breast cancer	Amgen	Completed	Met primary
Phase 3	NCT00439244	Dec 2006 → Feb 2009	osteoporosis	Novartis	Completed	No outcome recorded
Phase 3	NCT00439647	Dec 2006 → Oct 2010	osteoporosis	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT00391950	Oct 2006 → May 2007	prostate cancer	Novartis	Terminated	No outcome recorded
Phase 3	NCT00404820	Oct 2006 → Dec 2008	osteoporosis	Novartis	Completed	No outcome recorded
Phase 3	NCT00365105	Jul 2006 → Jan 2012	breast cancer, lung cancer, metastatic malignant neoplasm, prostate cancer	Radiation Therapy Oncology Group	Completed	Missed primary
Phase 3	NCT00320710	Feb 2006 → Jul 2013	breast cancer	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT00375427	Feb 2006 → Feb 2010	breast carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00352846	Jan 2006 → Sep 2011	non-Hodgkin lymphoma	M.D. Anderson Cancer Center	Completed	Met primary
Phase 3	NCT00332709	Jan 2006 → Aug 2010	postmenopausal osteoporosis	Novartis	Completed	No outcome recorded
Phase 3	NCT00242567	Dec 2005 → Jan 2012	prostate cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00375505	Oct 2005 → May 2014	breast cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00712985	Sep 2005 → Mar 2011	breast cancer	Milton S. Hershey Medical Center	Completed	No outcome recorded
Phase 3	NCT00376740	Sep 2005 → Nov 2010	breast cancer	Soroka University Medical Center	Completed	Met primary
Phase 3	NCT02181101	Sep 2005 → Sep 2013	breast neoplasm	Ludwig-Maximilians - University of Munich	Completed	Missed primary
Phase 3	NCT00219258	Jul 2005 → ?	—	Novartis	Completed	No outcome recorded
Phase 3	NCT00127205	Jul 2005 → Dec 2017	breast cancer	SWOG Cancer Research Network	Completed	Missed primary
Phase 3	NCT00375648	Jun 2005 → Jul 2007	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00145327	May 2005 → Nov 2009	osteoporosis	Novartis	Completed	Met primary
Phase 3	NCT00172042	Mar 2005 → May 2010	non-small cell lung carcinoma	Novartis Pharmaceuticals	Completed	Missed primary
Phase 3	NCT00107263	Jan 2005 → Mar 2007	breast cancer, osteoporosis	Alliance for Clinical Trials in Oncology	Completed	Met primary
Phase 3	NCT00172055	Dec 2004 → Jul 2009	prostate cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00798473	Sep 2004 → Sep 2007	Crohn disease, osteoporosis	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
Phase 3	NCT00132808	Jul 2004 → Feb 2008	osteoporosis	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT00100620	Jun 2004 → Apr 2007	corticosteroid-induced osteoporosis	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT00171639	Jun 2004 → Mar 2007	prostate cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00100555	Jun 2004 → Jun 2005	osteoporosis	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00097812	May 2004 → Dec 2005	osteoporosis	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00097825	Apr 2004 → Aug 2007	osteoporosis	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00086268	Apr 2004 → Oct 2007	non-small cell lung carcinoma	Novartis Pharmaceuticals	Completed	Missed primary
Phase 3	NCT00171314	Mar 2004 → Nov 2010	breast cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00412022	Mar 2004 → Nov 2024	breast cancer	National Cancer Institute, Naples	Unknown	Met primary
Phase 3	NCT00079001	Jan 2004 → Jul 2012	metastatic malignant neoplasm, prostate cancer	Alliance for Clinical Trials in Oncology	Completed	Missed primary
Phase 3	NCT00294437	Dec 2003	prostate cancer	Central European Cooperative Oncology Group	Terminated	No outcome recorded Stop: Business
Phase 3	NCT00193856	Oct 2003 → Aug 2017	prostate cancer	Trans Tasman Radiation Oncology Group	Completed	Mixed
Phase 3	NCT00072020	Aug 2003 → ?	breast cancer, metastatic malignant neoplasm	University of Sheffield	Unknown	Missed primary
Phase 3	NCT00432458	Jul 2003 → Jun 2011	plasma cell myeloma	Mayo Clinic	Completed	Met primary
Phase 3	NCT00202059	Jun 2003 → Sep 2007	female breast carcinoma	HealthPartners Institute	Completed	Met primary
Phase 3	NCT00171340	May 2003 → Feb 2010	breast cancer, disease of bone structure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00058188	Mar 2003 → Nov 2008	osteoporosis, prostate cancer	Northwestern University	Terminated	No outcome recorded
Phase 3	NCT00050011	Sep 2002 → Jan 2009	breast neoplasm, osteoporosis	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00130494	Aug 2002 → Nov 2006	breast cancer, metastatic neoplasm	Spanish Breast Cancer Research Group	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00372710	Aug 2002 → ?	breast carcinoma	Novartis	Terminated	No outcome recorded
Phase 3	NCT00103740	Apr 2002 → Dec 2003	bone Paget disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00046254	Feb 2002 → Feb 2007	osteoporosis	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT00049829	Jan 2002 → Jun 2006	osteoporosis	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT00022087	Dec 2001 → Mar 2007	breast cancer, osteoporosis	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 3	NCT00049452	Dec 2001 → Aug 2008	breast cancer, osteoporosis	Herbert Irving Comprehensive Cancer Center	Completed	Met primary
Phase 3	NCT00051636	Jan 2001 → Mar 2004	bone Paget disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00171925	Aug 2000 → Nov 2008	plasma cell myeloma	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00005073	Sep 1999 → Mar 2003	prostate cancer	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT00003884	Aug 1998 → Jan 2001	humoral hypercalcemia of malignancy, lung neoplasm, metastatic malignant neoplasm	Novartis	Completed	No outcome recorded

Phase 456 trials · 1 met primary · 3 missed
Phase 4	NCT06762730	Dec 2024 → Dec 2028 expected	—	Hadassah Medical Organization	Recruiting	No outcome recorded
Phase 4	NCT06051344	Jan → Dec 2023	osteoarthritis, knee	Toufiqe-E-Ealahi	Unknown	No outcome recorded
Phase 4	NCT05493267	Aug 2022 → Aug 2025 overdue	multidrug-resistant tuberculosis	Shanghai Pulmonary Hospital, Shanghai, China	Recruiting	No outcome recorded
Phase 4	NCT05025293	Dec 2021 → Mar 2026	osteoporosis	Lene Bergendal Solberg	Unknown	No outcome recorded
Phase 4	NCT05091086	Nov 2021 → Dec 2025 overdue	osteoporosis	National Taiwan University Hospital	Active not recruiting	No outcome recorded
Phase 4	NCT04719650	Oct 2021 → Oct 2024	postmenopausal osteoporosis	Peking University Third Hospital	Unknown	No outcome recorded
Phase 4	NCT04115397	Jan 2020 → Dec 2021	rheumatic disorder	Karolinska Institutet	Unknown	No outcome recorded
Phase 4	NCT03868033	Apr 2019 → Jul 2023	osteoporosis	National Taiwan University Hospital	Completed	Missed primary
Phase 4	NCT03424239	Aug 2018 → Jan 2020	—	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT03158246	Jun 2017 → Dec 2019	postmenopausal osteoporosis	Cttq	Unknown	No outcome recorded
Phase 4	NCT03932071	Jan 2017 → Jan 2020	respiratory system cancer	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 4	NCT04149405	Jun 2016 → Dec 2017	periodontitis, postmenopausal osteoporosis	Ondokuz Mayıs University	Completed	No outcome recorded
Phase 4	NCT02589600	Jan 2016 → Jun 2022	postmenopausal osteoporosis	Susan L. Greenspan	Completed	Missed primary
Phase 4	NCT02333344	Jul 2015 → Jan 2020	—	Novartis Pharmaceuticals	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT02499237	Jul 2015 → Nov 2018	postmenopausal osteoporosis	424 General Military Hospital	Completed	No outcome recorded
Phase 4	NCT01702415	Oct 2013 → Dec 2015	cystic fibrosis	Papworth Hospital NHS Foundation Trust	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT01675089	Jul 2012 → Jul 2013	renal osteodystrophy	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 4	NCT01310465	Jan → Dec 2011	—	Fudan University	Unknown	No outcome recorded
Phase 4	NCT01129336	Jun 2010 → Aug 2012	Her2-receptor negative breast cancer, metastatic carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01087008	Apr 2010 → May 2013	plasma cell myeloma	PETHEMA Foundation	Completed	No outcome recorded
Phase 4	NCT00795483	Nov 2009 → Nov 2011	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 4	NCT00774020	Oct 2008 → Jan 2011	bone Paget disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00740129	Oct 2008 → Mar 2011	bone Paget disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00762346	Sep 2008 → Mar 2013	metastatic carcinoma in the bone, non-small cell lung carcinoma	Sun Yat-sen University	Completed	No outcome recorded
Phase 4	NCT00745485	Aug 2008 → Jul 2010	osteoporosis	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00668200	May 2008 → Nov 2012	bone Paget disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00912938	Dec 2007 → Dec 2010	breast cancer	Korean Breast Cancer Study Group	Unknown	No outcome recorded
Phase 4	NCT00622505	Nov 2007 → Apr 2012	plasma cell myeloma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01218035	May 2007 → Dec 2010	osteoarthritis, hip	Turku University Hospital	Completed	No outcome recorded
Phase 4	NCT00434447	Dec 2006 → Sep 2009	bone neoplasm	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00375752	Jun 2006 → Dec 2010	breast neoplasm	Novartis Pharmaceuticals	Terminated	Missed primary
Phase 4	NCT00334139	May 2006 → Jul 2009	breast cancer, metastatic carcinoma in the bone, prostate cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02042872	May 2006 → Jul 2012	osteoporosis	James J. Peters Veterans Affairs Medical Center	Completed	No outcome recorded
Phase 4	NCT00333229	Mar 2006 → Dec 2013	breast cancer	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00391690	Feb 2006 → Dec 2010	prostate cancer	Novartis	Completed	No outcome recorded
Phase 4	NCT00434317	Aug 2005 → Apr 2008	metastatic neoplasm	Novartis	Completed	No outcome recorded
Phase 4	NCT01267279	Jan 2005 → Dec 2014	osteoporosis	Spokane Joint Replacement Center	Completed	No outcome recorded
Phase 4	NCT00099541	Nov 2004 → Nov 2007	non-small cell lung carcinoma, pleural neoplasm	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00104104	Oct 2004 → Oct 2007	plasma cell myeloma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00172003	Sep 2004 → Jul 2009	metastatic neoplasm, renal cell carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00242528	Apr 2004 → ?	plasma cell myeloma	Novartis	Withdrawn	No outcome recorded
Phase 4	NCT00346242	Mar 2004 → Mar 2006	thalassemia	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00172016	Jan 2004 → Apr 2005	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00237146	Nov 2003 → Mar 2008	prostate cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00219271	Sep 2003 → Sep 2009	prostate cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00241111	Sep 2003 → Jan 2006	metastatic prostate carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00219219	Sep 2003 → Oct 2006	prostate cancer	Novartis	Completed	No outcome recorded
Phase 4	NCT00063609	Apr 2003 → Apr 2005	prostate cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00172029	Apr 2003 → Sep 2005	breast carcinoma	Novartis	Completed	No outcome recorded
Phase 4	NCT00242554	Oct 2002 → Jul 2007	prostate cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00237159	Oct 2002 → Dec 2005	carcinoma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00164008	Oct 2002 → Dec 2005	disease related to solid organ transplantation, osteoporosis	Bayside Health	Completed	No outcome recorded
Phase 4	NCT00171964	May 2002 → Dec 2008	cancer, metastatic neoplasm	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00035997	Apr 2002 → Jan 2004	prostate cancer	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00029224	Oct 2001 → Nov 2002	breast cancer, plasma cell myeloma, prostate cancer	Novartis	Completed	No outcome recorded
Phase 4	NCT00114556	Feb 2000 → Aug 2004	osteoporosis	Royal Prince Alfred Hospital, Sydney, Australia	Completed	Met primary

Phase not applicable18 trials · 1 met primary
—	NCT06876636	Mar → Dec 2025 overdue	breast carcinoma	Xijing Hospital	Active not recruiting	No outcome recorded
—	NCT07546058	Dec 2024 → Nov 2025	malposition of teeth with or without hypodontia/oligodontia	Latakia University	Completed	No outcome recorded
—	NCT04498715	Jun 2021 → Jun 2024	—	Lithuanian University of Health Sciences	Unknown	No outcome recorded
—	NCT04652128	Jul 2019 → Jul 2022	stroke disorder	Yonsei University	Unknown	No outcome recorded
—	NCT02069340	Jun 2016 → Dec 2020	cancer, musculoskeletal system disorder	University of Southern California	Withdrawn	No outcome recorded
—	NCT02451462	Sep 2015 → Sep 2017	bone marrow disorder, disease related to hematopoietic stem cell transplant	Stanford University	Withdrawn	No outcome recorded
—	NCT01409811	Sep 2012 → Jan 2015	estrogen-receptor positive breast cancer, female breast carcinoma, invasive ductal breast carcinoma, progesterone-receptor positive breast cancer	City of Hope Medical Center	Terminated	No outcome recorded
—	NCT01772719	Aug 2012 → Nov 2016	plasma cell myeloma	University of Louisville	Terminated	No outcome recorded
—	NCT01572545	Apr → Sep 2012	postmenopausal osteoporosis	Aristotle University Of Thessaloniki	Completed	No outcome recorded
—	NCT02721940	Feb 2012 → Jan 2015	osteonecrosis	Chinese PLA General Hospital	Unknown	No outcome recorded
—	NCT00558012	Dec 2007 → Feb 2014	osteoporosis	University of Pittsburgh	Completed	Met primary
—	NCT00361595	Aug 2006 → Apr 2008	osteoporosis	The Cleveland Clinic	Completed	No outcome recorded
—	NCT00436917	Apr 2006 → Jun 2008	breast cancer, osteoporosis	Mayo Clinic	Completed	No outcome recorded
—	NCT00458796	Mar 2006 → ?	breast cancer, humoral hypercalcemia of malignancy, metastatic malignant neoplasm, musculoskeletal system disorder	University of Leeds	Terminated	No outcome recorded Stop: Enrollment
—	NCT00489905	Apr 2005 → May 2008	bone remodeling disease, prostate neoplasm	Hospital Authority, Hong Kong	Completed	No outcome recorded
—	NCT00114270	May 2004 → Jun 2007	breast cancer, osteoporosis	University of Virginia	Completed	No outcome recorded
—	NCT00126386	Jan 2004 → Sep 2006	cancer, hypercalcemia disease	Alberta Health services	Completed	No outcome recorded
—	NCT00087659	Dec 2003 → May 2007	prostate cancer	Novartis Pharmaceuticals	Completed	No outcome recorded

Comparator or background therapy88 trials
Phase 1	NCT06513624 Background	Dec 2024 → Dec 2026 expected	—	National University Hospital, Singapore	Recruiting	No outcome recorded
Phase 1	NCT02517918 Background	Feb 2015 → Sep 2016	osteosarcoma	Institut Bergonié	Completed	No outcome recorded
Phase 1	NCT01721993 Comparator	Jan 2013 → Jul 2014	—	Thar Pharmaceuticals, Inc	Completed	No outcome recorded
Phase 1	NCT00741377 Background	Jan 2009 → Dec 2011	plasma cell myeloma	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00415779 Background	Jul 2006 → Dec 2008	metastatic prostate carcinoma	National Cancer Institute, Naples	Completed	No outcome recorded
Phase 1	NCT00258258 Background	Aug 2005 → Mar 2009	plasma cell myeloma	Roswell Park Cancer Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT06374459 Comparator	Jan 2025 → May 2032 expected	hormone receptor-positive breast cancer	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 1/2	NCT06023420 Background	Feb → Dec 2024	bone neoplasm	Chinese University of Hong Kong	Unknown	No outcome recorded
Phase 1/2	NCT04279392 Comparator	Sep 2020 → Dec 2022	bone resorption disease	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT07043608 Background	May 2026 → Feb 2029 expected	clear cell renal carcinoma, metastatic carcinoma in the bone	Kelly Fitzgerald, MD	Not yet recruiting	No outcome recorded
Phase 2	NCT05677152 Comparator	Aug 2022 → Jul 2025 overdue	—	AUVA Traumazentrum Vienna Site UKH Meidling	Recruiting	No outcome recorded
Phase 2	NCT05328154 Comparator	Jun 2022 → Dec 2024	postmenopausal osteoporosis	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 2	NCT04608630 Comparator	Jul 2021 → Feb 2027 expected	osteoporosis	Australian and New Zealand Intensive Care Research Centre	Recruiting	No outcome recorded
Phase 2	NCT04325776 Comparator	Sep 2020 → May 2021	non-small cell lung carcinoma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT03396315 Comparator	Jan 2018 → Jun 2023	osteoporosis	Columbia University	Completed	No outcome recorded
Phase 2	NCT03183557 Comparator	Oct 2017 → Dec 2022	osteoporosis	Shinshu University	Unknown	No outcome recorded
Phase 2	NCT03118570 Background	Sep 2017 → Oct 2019	osteogenesis imperfecta type 1, osteogenesis imperfecta type 3, osteogenesis imperfecta type 4	Ultragenyx Pharmaceutical Inc	Completed	Mixed
Phase 2	NCT03127319 Comparator	Jul 2017 → Apr 2019	non-small cell lung carcinoma	Affiliated Hospital of Hebei University	Unknown	No outcome recorded
Phase 2	NCT02632916 Comparator	Aug 2016 → Feb 2020	osteoporosis	Children's Hospital of Eastern Ontario	Completed	No outcome recorded
Phase 2	NCT01951586 Comparator	Dec 2013 → Jul 2016	non-small cell lung carcinoma	Amgen	Completed	Missed primary
Phase 2	NCT01788176 Comparator	Dec 2013 → Dec 2015	complex regional pain syndrome	University of Sao Paulo General Hospital	Unknown	No outcome recorded
Phase 2	NCT01215344 Background	Nov 2010 → Nov 2015	plasma cell myeloma	Vanderbilt-Ingram Cancer Center	Completed	No outcome recorded
Phase 2	NCT00781261 Comparator	Aug 2009 → Dec 2013	osteonecrosis	University of Sydney	Unknown	No outcome recorded
Phase 2	NCT00903162 Background	May 2009 → Jul 2014	female breast carcinoma	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 2	NCT01330238 Comparator	Dec 2008 → Mar 2011	—	University of Oulu	Completed	No outcome recorded
Phase 2	NCT00399802 Comparator	Nov 2006 → Dec 2007	breast cancer, metastatic carcinoma in the bone	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00216151 Comparator	Jun 2005 → Mar 2007	plasma cell myeloma	Hoosier Cancer Research Network	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00091832 Comparator	Sep 2004 → Nov 2005	breast cancer, metastatic neoplasm	Amgen	Completed	Missed primary
Phase 2	NCT00081159 Background	Jul 2004 → Sep 2014	metastatic malignant neoplasm, prostate cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT00072930 Background	Dec 2003 → Apr 2007	prostate cancer	MedImmune LLC	Completed	No outcome recorded
Phase 2	NCT00181584 Comparator	Sep 2003 → Feb 2006	bone resorption disease, prostate cancer	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT00582556 Comparator	Apr 2003 → Mar 2011	prostate cancer	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 2	NCT01341262 Background	Mar 2002 → Oct 2007	plasma cell myeloma	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Completed	No outcome recorded
Phase 2/3	NCT01006395 Comparator	Jan 2011 → Apr 2019	prostate cancer	Austin Health	Completed	No outcome recorded
Phase 2/3	NCT00524849 Comparator	Nov 2006 → Aug 2008	breast cancer, metastatic carcinoma in the bone	Fudan University	Completed	No outcome recorded
Phase 3	NCT07056478 Comparator	Jan 2027 → Jan 2028 expected	pelvic muscle wasting	Prince of Wales Hospital, Shatin, Hong Kong	Not yet recruiting	No outcome recorded
Phase 3	NCT06533865 Background	Mar 2025 → Oct 2028 expected	functional hypothalamic amenorrhea	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 3	NCT04779216 Background	Sep 2021 → Oct 2024	anorexia nervosa, osteoporosis	Karen Klahr Miller, MD	Completed	Met primary
Phase 3	NCT04303026 Comparator	Mar 2020 → Jun 2023	osteoarthritis, hip	Vestre Viken Hospital Trust	Unknown	No outcome recorded
Phase 3	NCT04034199 Comparator	Aug 2019 → Dec 2020	idiopathic inflammatory myopathy, osteoporosis	Kwong Wah Hospital	Unknown	No outcome recorded
Phase 3	NCT03930992 Background	Apr 2019 → Oct 2022	osteoporosis	University of Guadalajara	Completed	No outcome recorded
Phase 3	NCT03040765 Comparator	May 2018 → Apr 2019	beta-thalassemia major, osteoporosis	Hamad Medical Corporation	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02123264 Comparator	May 2014 → Jun 2018	rheumatoid arthritis	Carmen Gómez-Vaquero	Terminated	No outcome recorded
Phase 3	NCT01802658 Comparator	Nov 2012 → Dec 2016	abnormal mineralization disorder	Nantes University Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01345019 Comparator	May 2012 → Jul 2016	lytic metastatic bone lesion, plasma cell myeloma	Amgen	Completed	Met primary
Phase 3	NCT01348269 Comparator	May 2011 → Aug 2015	bone marrow disorder	Wuerzburg University Hospital	Completed	No outcome recorded
Phase 3	NCT00330759 Comparator	Jun 2006 → Apr 2009	lytic metastatic bone lesion	Amgen	Completed	Met primary
Phase 3	NCT00321620 Comparator	Apr 2006 → Oct 2009	metastatic carcinoma in the bone	Amgen	Completed	Met primary
Phase 3	NCT00321464 Comparator	Apr 2006 → Jul 2009	metastatic carcinoma in the bone	Amgen	Completed	Met primary
Phase 3	NCT00326820 Comparator	Jan 2006 → Dec 2012	breast cancer, humoral hypercalcemia of malignancy, metastatic malignant neoplasm	Wales Cancer Trials Unit	Unknown	Missed primary
Phase 3	NCT00099177 Comparator	Aug 2005 → Dec 2007	bone neoplasm, metastatic malignant neoplasm	Hoffmann-La Roche	Terminated	No outcome recorded
Phase 3	NCT00099203 Comparator	Jul 2005 → Dec 2007	bone neoplasm, metastatic neoplasm	Hoffmann-La Roche	Terminated	No outcome recorded
Phase 3	NCT00512993 Comparator	Dec 2004 → Nov 2013	breast cancer	GBG Forschungs GmbH	Completed	No outcome recorded
Phase 3	NCT00145275 Background	Dec 2004 → Oct 2005	—	Novartis	Completed	No outcome recorded
Phase 3	NCT00215943 Comparator	Jun 2003 → Aug 2012	plasma cell myeloma	H. Lee Moffitt Cancer Center and Research Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00033332 Background	Apr 2002 → Mar 2006	plasma cell myeloma	National Cancer Institute (NCI)	Completed	Met primary
Phase 3	NCT00295646 Comparator	Jun 1999 → Mar 2008	breast cancer	Austrian Breast & Colorectal Cancer Study Group	Completed	No outcome recorded
Phase 4	NCT07406685 Comparator	Mar 2026 → Mar 2030 expected	postmenopausal osteoporosis	National Taiwan University Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT06859580 Comparator	Mar 2025 → Feb 2028 expected	primary hyperparathyroidism	University of Aarhus	Recruiting	No outcome recorded
Phase 4	NCT06643780 Comparator	Apr 2024 → Apr 2027 expected	pelvic muscle wasting	Prince of Wales Hospital, Shatin, Hong Kong	Recruiting	No outcome recorded
Phase 4	NCT06118905 Comparator	Feb 2024 → Feb 2029 expected	osteoporosis	Chrissy Kistler	Recruiting	No outcome recorded
Phase 4	NCT06135298 Background	Dec 2023 → Jul 2025	osteoporosis	Aksaray University	Completed	No outcome recorded
Phase 4	NCT05666310 Comparator	Feb 2023 → Jan 2026 overdue	muscular atrophy, osteoporosis	Nami Safai Haeri	Active not recruiting	No outcome recorded
Phase 4	NCT05361408 Comparator	Feb 2022 → Feb 2024	osteoporosis	Yonsei University	Completed	No outcome recorded
Phase 4	NCT05058976 Background	Sep 2021 → Mar 2027 expected	postmenopausal osteoporosis	Susan L. Greenspan	Active not recruiting	No outcome recorded
Phase 4	NCT05598606 Comparator	Jan 2021 → Jan 2023	drug pseudoallergy	Shenzhen People's Hospital	Completed	No outcome recorded
Phase 4	NCT04597931 Comparator	Nov 2020 → Nov 2023	osteoporosis, spinal cord injury	Sheba Medical Center	Unknown	No outcome recorded
Phase 4	NCT04087096 Background	Aug 2020 → Aug 2024	disease of bone structure	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT04177940 Comparator	Aug 2020 → Jul 2024	osteoporosis	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 4	NCT03924414 Comparator	Nov 2019 → Feb 2026	Lewy body dementia, Parkinson disease, extrapyramidal and movement disease, multiple system atrophy +3	California Pacific Medical Center Research Institute	Completed	No outcome recorded
Phase 4	NCT02480634 Background	Jun 2019 → Sep 2021	metastatic carcinoma in the bone, non-small cell lung carcinoma	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	Unknown	No outcome recorded
Phase 4	NCT04085419 Comparator	May 2019 → May 2023	osteoporosis, primary hyperparathyroidism	University Medical Centre Ljubljana	Unknown	No outcome recorded
Phase 4	NCT03576599 Comparator	Jun 2017 → Jun 2019	bone disorder	Oslo University Hospital	Terminated	No outcome recorded
Phase 4	NCT03087851 Comparator	Mar 2017 → Aug 2020	osteoporosis	Aarhus University Hospital	Completed	No outcome recorded
Phase 4	NCT03735537 Comparator	Nov 2016 → Feb 2025	osteogenesis imperfecta	University of Edinburgh	Completed	No outcome recorded
Phase 4	NCT02286830 Comparator	Jan 2015 → Feb 2023	plasma cell myeloma	Thomas Lund	Completed	No outcome recorded
Phase 4	NCT02176382 Comparator	Aug 2014 → Feb 2020	postmenopausal osteoporosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01732770 Comparator	Nov 2012 → Jan 2015	postmenopausal osteoporosis	Amgen	Completed	No outcome recorded
Phase 4	NCT01907880 Comparator	Aug 2012 → Jan 2016	breast cancer	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 4	NCT00927186 Comparator	Jul 2009 → Oct 2010	postmenopausal osteoporosis	Eli Lilly and Company	Completed	Met primary
Phase 4	NCT00765687 Comparator	Aug 2008 → May 2012	metastatic carcinoma in the bone, non-small cell lung carcinoma	Sun Yat-sen University	Completed	No outcome recorded
Phase 4	NCT01153425 Comparator	Jul 2008 → Dec 2012	osteoporosis	University of Pennsylvania	Completed	No outcome recorded
Phase 4	NCT00431444 Comparator	Jan 2007 → Jul 2008	osteoporosis	Novartis	Completed	No outcome recorded
Phase 4	NCT00733538 Comparator	Dec 2004 → Nov 2009	plasma cell myeloma	Centre Hospitalier Universitaire de Nice	Completed	No outcome recorded
—	NCT05906056 Background	May 2023 → Apr 2026 overdue	spinal cord injury, stroke disorder, traumatic brain injury	University of Ioannina	Recruiting	No outcome recorded
—	NCT07823751 Background	Apr 2021 → Apr 2023	breast carcinoma	Universitas Indonesia	Completed	No outcome recorded
—	NCT00580047 Comparator	Dec 2003 → Jul 2014	impaired renal function disease	University of Nebraska	Completed	No outcome recorded
—	NCT00520052 Comparator	Aug 2003 → Aug 2005	osteoporosis	Wirral University Teaching Hospital NHS Trust	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 8

Date	Issuer	Release
2018-02-08	Amgen	Results Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology amgen.com ↗ In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85-1.14).
2017-06-04	Amgen	Results Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017 amgen.com ↗ The study met its primary endpoint, demonstrating XGEVA is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p =0.01).
2017-04-01	Amgen	Results Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab) amgen.com ↗ In the same oral session, Amgen and UCB presented results from a separate analysis of the Phase 2 study (OR08-2) showing BMD gains from prior EVENITY treatment were generally maintained for two years (months 48 to 72) when followed by a single dose of zoledronic acid.
2017-03-03	Amgen	Results Amgen Presents New Data From Phase 3 XGEVA® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop amgen.com ↗ In this study, XGEVA ® (denosumab) met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p= 0.01).
2015-10-11	Amgen	Results New Data Show Greater Bone Mineral Density Gains With Prolia® (Denosumab) Compared With Zoledronic Acid amgen.com ↗ The change from baseline in lumbar spine BMD at 12 months – the primary endpoint – in the denosumab group was significantly greater than that in the zoledronic acid group: 3.2 percent vs. 1.1 percent, respectively ( p <0.0001).
2012-10-15	Eli Lilly and Company	Results Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO® (teriparatide [rDNA origin] injection) and Zoledronic Acid lilly.com ↗ Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months in postmenopausal women with osteoporosis, based on additional analysis of data from the SHOTZ trial.
2011-09-19	Eli Lilly and Company	Results New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid lilly.com ↗ Dynamic indices of bone formation, including mineralizing surface/bone surface (MS/BS) and bone formation rate (BFR), were significantly higher in women treated with FORTEO than in women treated with zoledronic acid at six months.
2008-04-16	Halozyme Therapeutics	Results Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference halozyme.com ↗ In rodent intradermal models, the maximal concentration of bisphosphonates that could be administered without producing ISRs was increased 3- to 5-fold when co-administered in combination with rHuPH20.

All press releases naming this drug 9 releases

Date	Issuer	Release
2018-02-08	Amgen	Results From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology amgen.com ↗
2017-06-04	Amgen	Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017 amgen.com ↗
2017-04-01	Amgen	Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab) amgen.com ↗
2017-03-03	Amgen	Amgen Presents New Data From Phase 3 XGEVA® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop amgen.com ↗
2015-10-11	Amgen	New Data Show Greater Bone Mineral Density Gains With Prolia® (Denosumab) Compared With Zoledronic Acid amgen.com ↗
2014-11-11	Daewoong Pharmaceutical Co. LTD.	Daewoong Pharmaceutical signed strategic tie-up with Sandoz Korea for ‘Sandoz Zoledronic acid Injection’, an osteoporosis treatment agent daewoong.co.kr ↗
2012-10-15	Eli Lilly and Company	Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO® (teriparatide [rDNA origin] injection) and Zoledronic Acid lilly.com ↗
2011-09-19	Eli Lilly and Company	New Data Explore Mechanistic Differences Between FORTEO® and Zoledronic Acid lilly.com ↗
2008-04-16	Halozyme Therapeutics	Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference halozyme.com ↗

Evidence & citations 20 cited values

Every value below carries the sentence it was read from. 339 sources stand behind the page.

Field	Value	Cited text
Known as	zoledronic acid	“The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.” NCT00489905 ↗ 314 “The use of zoledronic acid (Zometa) has an established place in the management of malignancies with a predilection for skeletal involvement (in particular metastasis).” NCT01367288 ↗ “Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles.” NCT01204203 ↗ “Zoledronic acid, Aclasta® 5 mg will be administered intravenously according to standard management criteria in order to obtain an homogeneous population.” NCT05328154 ↗ “Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.” PMID 23047045 ↗ Oct 2012 “Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid” NCT00091832 ↗ “Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.” NCT01129336 ↗ “IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase.” NCT00104650 ↗ “Zoledronic Acid (Zometa), a new generation, highly potent bisphosphonate used to treat osteoporosis and hypercalcemia of malignancy” NCT00206388 ↗ “2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvant treatment plus zoledronic acid 4 mg i.v. q4w” NCT00375752 ↗ “1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).” NCT03930992 ↗ Show 304 more sources
Known as	acid zoledronique	“The investigators offer a study phase 2 of the effectiveness of N-BP (acid zoledronique) on the prevention of the local recurrence” NCT01564121 ↗
Known as	Acide zoledronic	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01219790 ↗
Known as	Acide Zoledronique	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02739555 ↗
Known as	aclasta	“Zoledronic acid, Aclasta® 5 mg will be administered intravenously according to standard management criteria in order to obtain an homogeneous population.” NCT05328154 ↗ 10 “Group 1: Experimental group 30 cases, Aclasta® (Zoledronic acid 5mg/100ml) is given intravenously on the 4th postoperative day” NCT02838121 ↗ “Patients will be randomised 1:1 to receive either one infusion aclasta (5 mg zolendronic acid, n=40) or placebo (n=40).” NCT04115397 ↗ “Novartis Pharmaceuticals Australia provided ampoules of zoledronic acid (Aclasta®) and matching placebo without cost.” PMID 34104395 ↗ May 2021 “Zoledronic acid (Aclasta) is a drug known for its protective effect in some bone diseases (tumors, paget).” NCT00100620 ↗ “zoledronic acid 5 mg (Aclasta®) administered as single intravenous infusion (100 ml): Verum” NCT05677152 ↗ “Plus a single dose of zoledronic acid (Aclasta) once the diagnosis of HO is made.” NCT05906056 ↗ “alternating use of Prolia (Denosumab) and Aclasta (Zoledronic acid)” NCT05091086 ↗ “Zoledronic acide (Aclasta)” NCT07056478 ↗ “zoledronic acid (aclasta)” NCT00939900 ↗ NCT01348269 ↗
Known as	AK156	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01522521 ↗
Known as	CGP42446	“Zoledronic acid (Zometa®, CGP42446) is a member of a class of compounds known as bisphosphonates.” NCT00264420 ↗ 1 “Zoledronic acid (Zometa®, CGP42446) is the most potent clinically available bisphosphonates” NCT00216151 ↗
Known as	Reclast	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00668200 ↗
Known as	ZLD	“Bisphosphonates such as zoledronic acid (ZLD) reduce skeletal events in MM” PMID 22902362 ↗ Aug 2012
Known as	ZOL	“To bridge this knowledge gap we propose to conduct a 1-year, randomized, double-blind, active-controlled trial to test the efficacy of DEMAB (expected active muscle agent)...” NCT06118905 ↗ 9 “We randomized 63 nonosteoporotic, ART-naive adults with HIV initiating ART with atazanavir/ritonavir + tenofovir/emtricitabine to a single zoledronic acid (ZOL) infusion (5 mg)...” PMID 27193748 ↗ May 2016 “This study is a randomized, double-blinded, placebo-controlled trial investigating the effects of zoledronic acid (ZOL) versus placebo in patients with primary...” NCT06859580 ↗ “A post hoc analysis of the HORIZON Recurrent Fracture Trial was done to determine the effect of zoledronic acid (ZOL) on total hip (TH) and femoral neck (FN) BMD in subgroups...” PMID 24839241 ↗ Dec 2014 “The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with...” PMID 21394500 ↗ Mar 2011 “A single infusion of zoledronic acid (ZOL) after acute spinal cord injury (SCI) attenuates bone loss at the hip (proximal femur) and knee (distal femur and proximal tibia) for...” PMID 34278611 ↗ Jul 2021 “To develop a pharmacometric model to predict jawbone zoledronic acid (Zol) concentrations in oncologic patients” NCT02069340 ↗ “three bisphosphonate (BP) treatments: risedronate (RIS), alendronate (ALN), and zoledronic acid (ZOL)” PMID 36602607 ↗ Jan 2023 “neoadjuvant chemotherapy +/- zoledronic acid (ZOL) in invasive breast cancer” PMID 23515409 ↗ Mar 2013 “treated with 5 milligrams of zoledronic acid (ZOL) once yearly” PMID 21037195 ↗ Nov 2010
Known as	ZOL446	“Reclast (ZOL446, zoledronic acid)” NCT00668200 ↗ 2 “ZOL446 (zoledronic acid)” NCT00172016 ↗ “Zoledronic acid (ZOL446)” NCT00171925 ↗
Known as	zoledronate	“The purpose of the HOBOE study, Version 1, was to compare the adjuvant hormonal therapy treatments of Tamoxifen, Letrozole and Letrozole + Zoledronate for their effects on bone...” NCT00412022 ↗ 6 “Zoledronate is a third generation aminobiphosphonate (BP), probably the most powerful among the available compounds which received market clearance authorisation in MM with bone damage.” NCT00733538 ↗ “Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.” PMID 23047045 ↗ Oct 2012 “The aim of this study was to compare zoledronic acid (zoledronate) and alendronate for prevention of transplantation bone loss.” PMID 23024190 ↗ Sep 2012 “Zoledronate, which is licensed for use, is administered intravenously once a year which should be easier to administer.” NCT01702415 ↗ “patients receive zoledronate IV over at least 15 minutes once every 3 months during months 1-24” NCT00022087 ↗ “Group 1: Zoledronate plus calcium and vit D supplementation” NCT00114556 ↗
Known as	zoledronic	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03127319 ↗
Known as	Zoledronic acid (Zometa, Reclast, Zomera)	“Zoledronic acid (Zometa, Reclast, Zomera)” NCT01332617 ↗
Known as	Zoledronic Acid Injection	“Drug: Zoledronic Acid Injection” NCT04325776 ↗ 1 “Drug: Zoledronic Acid Injection” NCT04719650 ↗
Known as	zolendronic acid	“Patients will be randomised 1:1 to receive either one infusion aclasta (5 mg zolendronic acid, n=40) or placebo (n=40).” NCT04115397 ↗
Known as	Zometa	“Patients will be randomized to receive either 4 herbs formula plus Zometa or Zometa alone after all the eligibility criteria have been fulfilled and informed consent has been signed.” NCT06023420 ↗ 25 “The use of zoledronic acid (Zometa) has an established place in the management of malignancies with a predilection for skeletal involvement (in particular metastasis).” NCT01367288 ↗ “Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles.” NCT01204203 ↗ “Efficacy and Tolerability of Intravenous Zometa® (Zoledronic Acid) 4 mg in Primary Breast Cancer Patients With Disseminated Tumor Cells in Bone Marrow.” NCT00172068 ↗ “the study drugs thalidomide and Zometa (zoledronic acid) were provided by Celgene Pharmaceuticals and Novartis Oncology, respectively” PMID 22902362 ↗ Aug 2012 “Patients will be treated every 3 weeks with 4 mg zoledronic acid (Zometa), administered by a 15 min. intravenous infusion.” NCT00287261 ↗ “six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC) and zoledronic acid (Zometa)” NCT01099436 ↗ “Intravenous Paricalcitol (ZEMPLAR™) [19-NOR-1 ALPHA, 25 - (OH)D] With Zoledronic Acid (Zometa™)” NCT00258258 ↗ “Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months.” NCT00083382 ↗ “Zoledronic acid (Zometa®, CGP42446) is the most potent clinically available bisphosphonates” NCT00216151 ↗ “Zoledronic acid (Zometa) belongs to a class of drugs called bisphosphonates.” NCT00264420 ↗ Show 15 more sources
Action	Inhibit	“The mechanism of action of nitrogen-containing bisphosphonates such as pamidronate and zoledronic acid appears to involve inhibition of the mevalonate pathway” NCT00295867 ↗
Modality	Other / unclassified	“Bisphosphonates reduce bone metastases in postmenopausal women with early-stage breast cancer” PMID 32929540 ↗ Sep 2020
Route	Intravenous	“zoledronate IV monthly” NCT00004928 ↗